RNA is upstream of all biology and thus presents a vast array of therapeutically attractive targets.  Most therapeutic agents that bind directly to RNA are either antibiotics blocking bacterial ribosome function or oligonucleotides with their attendant pharmaceutical limitations.  At Arrakis we identified druggable RNA sub-structures in mRNA and orally available small molecules that bind to those structures selectively and thereby modulate mRNA function.  In addition to highlighting some of the unique challenges of drugging RNA, this presentation will place this work in a larger context of chemistry-driven innovation as a path to new therapeutics.

Drugging RNA: Novel therapeutics via chemistry innovation

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.